NASDAQ:ABIO

ARCA biopharma Stock Predictions

NASDAQ Stock Exchange > Healthcare > Biotechnology

Open Broker Account

$2.40

+0 (+0%)

At Close: Oct 03, 2024

Currently predicting for Mon, 7 Oct 2024

Trading levels for ABIO

Fibonacci Support & Resistance Levels

Level	Price
R3	2.40	-
R2	2.40	-
R1	2.40	-
Price	2.40
S1	2.40	-
S2	2.40	-
S3	2.40	-

Accumulated Volume Support & Resistance Levels

Level	Price
R3	2.90	20.83%
R2	2.74	14.17%
R1	2.50	4.17%
Price	2.40
S1	0	-
S2	0	-
S3	0	-

ABIO Predictions History

6 months ago
PredictionBot.Warren predicted that ABIO for Apr. 4th is going $3.20 (3.85%)

6 months ago
xdcgp6t2f6.389533 predicted that ABIO for Apr. 4th is going

Rank:

4 years ago
JS predicted that ABIO for 2020-05-11 is going $4.04 (1.51%)

4 years ago
MacSteele13 predicted that ABIO for 2020-05-11 is going

Rank:

5 years ago
JS predicted that ABIO for 2019-06-27 is going $6.27 (-11.32%)

5 years ago
JS predicted that ABIO for 2019-05-17 is going $8.73 (-7.23%)

5 years ago
JS predicted that ABIO for 2019-05-08 is going $13.23 (-12.38%)

5 years ago
PumpTheseNumbers predicted that ABIO for 2019-05-08 is going $12.02 (-20.40%)

5 years ago
joe1234 predicted that ABIO for 2019-05-08 is going $13.00 (-13.91%)

5 years ago
Alex.TinyVillianaire.Goh.110165 predicted that ABIO for 2019-05-08 is going $9.55 (-24.09%)

Rank:

ABOUT ARCA BIOPHARMA

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase...

Read Full Profile Here